BRPI0821003A2 - Método para aumentar a imunorreatividade - Google Patents

Método para aumentar a imunorreatividade

Info

Publication number
BRPI0821003A2
BRPI0821003A2 BRPI0821003-9A BRPI0821003A BRPI0821003A2 BR PI0821003 A2 BRPI0821003 A2 BR PI0821003A2 BR PI0821003 A BRPI0821003 A BR PI0821003A BR PI0821003 A2 BRPI0821003 A2 BR PI0821003A2
Authority
BR
Brazil
Prior art keywords
increase immunoreactivity
immunoreactivity
increase
Prior art date
Application number
BRPI0821003-9A
Other languages
English (en)
Inventor
Gottfried Baier
Hans Loibner
Manfred Schuster
Günther Lametschwandtner
Dominik Wolf
Original Assignee
Medizinische Universität Innsbruck
Apeiron Biologics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Universität Innsbruck, Apeiron Biologics Ag filed Critical Medizinische Universität Innsbruck
Publication of BRPI0821003A2 publication Critical patent/BRPI0821003A2/pt
Publication of BRPI0821003B1 publication Critical patent/BRPI0821003B1/pt
Publication of BRPI0821003B8 publication Critical patent/BRPI0821003B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0821003A 2007-12-10 2008-12-10 método para aumentar a imunorreatividade BRPI0821003B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0199607A AT506041A1 (de) 2007-12-10 2007-12-10 Verfahren zur erhöhung der immunreaktivität
ATA1996/2007 2007-12-10
PCT/AT2008/000443 WO2009073905A2 (de) 2007-12-10 2008-12-10 Verfahren zur erhöhung der immunreaktivität

Publications (3)

Publication Number Publication Date
BRPI0821003A2 true BRPI0821003A2 (pt) 2015-06-16
BRPI0821003B1 BRPI0821003B1 (pt) 2019-03-26
BRPI0821003B8 BRPI0821003B8 (pt) 2021-05-25

Family

ID=40585504

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821003A BRPI0821003B8 (pt) 2007-12-10 2008-12-10 método para aumentar a imunorreatividade

Country Status (25)

Country Link
US (1) US8809288B2 (pt)
EP (2) EP2220214B1 (pt)
JP (2) JP6118491B2 (pt)
KR (1) KR101692797B1 (pt)
CN (2) CN101918544B (pt)
AT (1) AT506041A1 (pt)
AU (1) AU2008336276C1 (pt)
BR (1) BRPI0821003B8 (pt)
CA (1) CA2708343C (pt)
CY (1) CY1120136T1 (pt)
DK (1) DK2220214T3 (pt)
EA (1) EA018966B1 (pt)
ES (1) ES2665928T3 (pt)
HR (1) HRP20180558T1 (pt)
HU (1) HUE037235T2 (pt)
IL (1) IL206155A (pt)
LT (1) LT2220214T (pt)
MX (1) MX2010006296A (pt)
NZ (1) NZ585646A (pt)
PL (1) PL2220214T3 (pt)
PT (1) PT2220214T (pt)
RS (1) RS56941B1 (pt)
SI (1) SI2220214T1 (pt)
WO (1) WO2009073905A2 (pt)
ZA (1) ZA201003791B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008033403A2 (en) 2006-09-13 2008-03-20 The Trustees Of Columbia University In The City Of New York Agents and methods to elicit anti-tumor immune response
AT506041A1 (de) * 2007-12-10 2009-05-15 Univ Innsbruck Verfahren zur erhöhung der immunreaktivität
EP2471548A1 (de) 2010-12-28 2012-07-04 Apeiron Biologics AG siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs
CN102552891A (zh) * 2011-12-27 2012-07-11 陆华 热休克凋亡脑胶质瘤负载树突状细胞肿瘤疫苗的制备方法
US9890215B2 (en) * 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
CA3051222C (en) * 2013-06-10 2023-01-24 Dana-Farber Cancer Institute, Inc. Methods and compositions for reducing immunosupression by tumor cells
US10145908B2 (en) 2013-07-19 2018-12-04 Allegro Microsystems, Llc Method and apparatus for magnetic sensor producing a changing magnetic field
EP3254701A1 (en) 2016-06-09 2017-12-13 IMBA-Institut für Molekulare Biotechnologie GmbH Cbl-b inhibitor comprising a cbl-b binding peptide for the prevention or treatment of fungal infections
JP2020503043A (ja) * 2016-12-30 2020-01-30 セルラリティ インコーポレイテッド 遺伝子改変されたナチュラルキラー細胞
EP3724327A4 (en) * 2017-12-14 2022-01-12 EZY Biotech LLC SUBJECT-SPECIFIC TUMOR-INHIBITING CELLS AND THEIR USE
MX2021004191A (es) 2018-10-15 2021-05-27 Nurix Therapeutics Inc Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
US12582722B2 (en) 2019-02-13 2026-03-24 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
CA3136348A1 (en) 2019-04-09 2020-10-15 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
AU2020278592B2 (en) 2019-05-17 2024-10-10 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof
MX2021015675A (es) 2019-06-26 2022-02-03 Nurix Therapeutics Inc Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos.
AU2020320195A1 (en) * 2019-07-30 2022-03-10 Nurix Therapeutics, Inc. Urea, amide, and substituted heteroaryl compounds for Cbl-b inhibition
EP4034140A1 (en) 2019-09-24 2022-08-03 Nurix Therapeutics, Inc. Cbl inhibitors and compositions for use in adoptive cell therapy
WO2021113557A1 (en) 2019-12-04 2021-06-10 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
WO2022217123A2 (en) 2021-04-08 2022-10-13 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds
CN115554290B (zh) * 2021-07-01 2025-02-14 中国科学院分子细胞科学卓越创新中心 五羟色胺或其受体激动剂在治疗ilc2细胞介导的免疫性疾病中的应用
CA3236073A1 (en) 2021-10-26 2023-05-04 Robert J. Brown Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk
EP4289939A1 (en) 2022-06-10 2023-12-13 Apeiron Biologics AG Population of transfected immune cells and method for their production
CN121866324A (zh) 2023-09-13 2026-04-14 格拉茨医科大学 提供抗原反应性淋巴细胞的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050037989A1 (en) * 2001-08-27 2005-02-17 Lewis David L. Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
WO2004024063A2 (en) * 2002-09-11 2004-03-25 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1646644A4 (en) 2003-03-03 2007-05-16 Proteologics Inc POSH INTERACTIVE PROTEINS AND CORRESPONDING METHODS
US20070054355A1 (en) * 2003-03-05 2007-03-08 Yuval Reiss Cbl-b polypeptides, complexes and related methods
ATE458485T1 (de) * 2003-07-11 2010-03-15 Proteologics Inc Ubiquitin-ligase-hemmer und verwandte verfahren
DE10347436B4 (de) * 2003-10-13 2007-08-02 Johann Wolfgang Goethe-Universität Frankfurt am Main In vitro Verfahren zur Diagnose der kardiovaskulären Funktionalität von Blut-abgeleiteter zirkulierender Vorläuferzellen (BDP)
US20070274915A1 (en) * 2003-10-17 2007-11-29 Anjana Rao Modulation Of Anergy And Methods For isolating Anergy-Modulating Compounds
WO2005069791A2 (en) * 2004-01-08 2005-08-04 Cedars-Sinai Medical Center Compositions and methods for enhancing the th1 response in connection with dendritic cell vaccines
JP2008522951A (ja) * 2004-07-19 2008-07-03 ベイラー・カレツジ・オブ・メデイシン サイトカインシグナル伝達調節物質の調節および免疫療法のための応用
US7868159B2 (en) 2005-06-23 2011-01-11 Baylor College Of Medicine Modulation of negative immune regulators and applications for immunotherapy
TWI368637B (en) * 2005-09-05 2012-07-21 Hon Hai Prec Ind Co Ltd High lustrous nano paint and methods for manufacturing and using the same
US20070087988A1 (en) 2005-09-30 2007-04-19 New York University Hematopoietic progenitor kinase 1 for modulation of an immune response
WO2008033403A2 (en) * 2006-09-13 2008-03-20 The Trustees Of Columbia University In The City Of New York Agents and methods to elicit anti-tumor immune response
AT506041A1 (de) * 2007-12-10 2009-05-15 Univ Innsbruck Verfahren zur erhöhung der immunreaktivität

Also Published As

Publication number Publication date
BRPI0821003B1 (pt) 2019-03-26
CN103898051B (zh) 2019-07-26
IL206155A (en) 2014-07-31
CA2708343A1 (en) 2009-06-18
HRP20180558T1 (hr) 2018-06-01
EP2220214A2 (de) 2010-08-25
CN101918544A (zh) 2010-12-15
NZ585646A (en) 2012-05-25
BRPI0821003B8 (pt) 2021-05-25
MX2010006296A (es) 2011-02-23
CY1120136T1 (el) 2018-12-12
JP2011507806A (ja) 2011-03-10
DK2220214T3 (en) 2018-04-16
AU2008336276B2 (en) 2014-06-12
EP2220214B1 (de) 2018-01-17
CN103898051A (zh) 2014-07-02
JP2015231371A (ja) 2015-12-24
ES2665928T3 (es) 2018-04-30
CA2708343C (en) 2018-09-04
PT2220214T (pt) 2018-04-23
IL206155A0 (en) 2010-12-30
WO2009073905A2 (de) 2009-06-18
JP6118491B2 (ja) 2017-04-19
AU2008336276C1 (en) 2015-01-15
SI2220214T1 (en) 2018-04-30
RS56941B1 (sr) 2018-05-31
AT506041A1 (de) 2009-05-15
WO2009073905A8 (de) 2009-09-03
HUE037235T2 (hu) 2018-08-28
KR20100110779A (ko) 2010-10-13
ZA201003791B (en) 2011-03-30
EA201000974A1 (ru) 2010-12-30
CN101918544B (zh) 2014-03-19
EA018966B1 (ru) 2013-12-30
KR101692797B1 (ko) 2017-01-05
AU2008336276A1 (en) 2009-06-18
PL2220214T3 (pl) 2018-07-31
JP6175103B2 (ja) 2017-08-02
WO2009073905A3 (de) 2009-10-22
US8809288B2 (en) 2014-08-19
LT2220214T (lt) 2018-03-26
US20100260808A1 (en) 2010-10-14
EP3363892A1 (de) 2018-08-22

Similar Documents

Publication Publication Date Title
BRPI0821003A2 (pt) Método para aumentar a imunorreatividade
BRPI1013482A2 (pt) método para produzir um composto
BRPI0906906A2 (pt) Método para preparar um composto e composto
BRPI1015166A2 (pt) método para usar um catalisador
BRPI0817547A2 (pt) Método para realizar pirólise
BRPI0818872A2 (pt) Método para prevenir efeitos adversos por glp-1
BRPI0923748A2 (pt) Método para a preparação de dióis
BRPI1007160A2 (pt) Método para esterilizar um material
BRPI0916973A2 (pt) anticorpos para ccr2
BRPI0920782A2 (pt) técnica para promover a fusão eficientes de instruções
EP2125512A4 (en) IMPROVEMENTS ON AIRPLANES
BRPI0819568A2 (pt) métodos para a preparação de um composto
BRPI0812999A2 (pt) Método para preparar um composto
BRPI0912167A2 (pt) método para recuperar um gás natural
BRPI1015147A2 (pt) métodos para melhorar a farmacocinética
BR112012009974A2 (pt) método para produzir grândulos que compreendem um perticida
BRPI0818049A2 (pt) Método para a preparação de nitratos orgânicos
BRPI1014267A2 (pt) processo para a carbonitrificação
BRPI0913136A2 (pt) método para produzir uma peça e peça.
PT2429502T (pt) Método e composição para melhorar a absorção de aspirina
BRPI0811844A2 (pt) Composto, e, método para tratar um paciente
BRPI0917866A2 (pt) métodos para intensificar o metabolismo energético
BRPI0917146A2 (pt) método para formar um pneumático recauchutado
BRPI1008308A2 (pt) processo para produzir um composto
BRPI0809688A2 (pt) Método para fornecer um alojamento de solenoide

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/03/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/03/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF